Pharmaceuticals

AstraZeneca Stock (AZN): Transformative Acquisition in Cancer Care

AstraZeneca acquires EsoBiotec for up to $1 billion, enhancing its cancer treatment portfolio with innovative cell therapies.

The Biotech Stocks Tackling the World’s Most Common Cancer

Medicus Pharma (NASDAQ: MDCX) joins Roche, Regeneron, and Bristol-Myers in the 360i BCC market matrix. Discover its breakthrough innovation in skin cancer care.

KalVista Pharmaceuticals Stock (KALV): Advancements in HAE Treatment and Regulatory Progress

KalVista announces promising third quarter results with sebetralstat's progress, pivotal for patients with hereditary angioedema.

TG Therapeutics Stock (TGTX): Advancing MS Treatment

TG Therapeutics announces key data presentations on BRIUMVI, its MS treatment, signaling growth potential for investors.

Enliven Therapeutics Stock (ELVN): Promising Advances in Oncology Pipeline

Enliven Therapeutics continues to progress in its oncology trials with key Phase 1 data readouts expected in 2025 and a strong cash runway into 2027—discover the latest updates now.

Mineralys Therapeutics Stock (MLYS): Strategic Offering to Fuel Growth

Mineralys Therapeutics has priced a public offering to raise $175 million to advance clinical development of innovative treatments.

Roche Stock (OTC: RHHBY): Strategic Collaboration for Obesity Treatment

Roche partners with Zealand Pharma to co-develop petrelintide, targeting the growing obesity market with promising therapeutic solutions.

Takeda Pharmaceutical Stock (NYSE: TAK): Strategic Focus on Oncology and Growth Opportunities

Takeda's revamped oncology strategy prioritizes key tumors and innovative partnerships, enhancing growth prospects and market positioning.

2Seventy Bio (TSVT): Surge Following Acquisition Announcement

2Seventy Bio jumps 77% as Bristol Myers Squibb announces a $5-per-share buyout. Learn how this deal reshapes biotech investing and what it means for you.

Encouraging Interim Data for Innovative Skin Cancer Patch

Medicus Pharma’s SkinJect patch showed promising clinical clearance in Phase 2 interim data. Could this novel treatment be a game-changer in skin cancer care?

Interim Data Update from Medicus Pharma’s Phase 2 Clinical Trial

Medicus Pharma reports a positive trend in its interim Phase 2 trial analysis for a revolutionary skin cancer treatment. Key details on this major breakthrough.

FAQs on Medicus Pharma's Interim Data Update - 6 March 2025

Medicus Pharma reports a positive trend in its interim Phase 2 trial analysis for a novel skin cancer treatment. Here are FAQs explaining this breakthrough.

High Demand, Few Options: The Skin Cancer Treatment Gap

Basal Cell Carcinoma is 7x more common than melanoma, yet patients remain underserved. Sun and fair skin fuel its rise. Explore a rising need for treatments.

How to Invest in Medicus Pharma

Medicus Pharma (MDCX) is developing a breakthrough skin cancer patch targeting a $15B+ market. Strong IP, Phase 2 progress - learn how to invest.

Walgreens Boots Alliance Inc. (WBA): Upcoming Acquisition by Sycamore Partners

Sycamore Partners nears a $10B Walgreens buyout, potentially breaking up the retail giant. What it means for investors, market dynamics, and strategic shifts.